Health Catalyst (NASDAQ:HCAT) Earns Equal Weight Rating from Wells Fargo & Company

Health Catalyst (NASDAQ:HCAT)‘s stock had its “equal weight” rating reiterated by analysts at Wells Fargo & Company in a research note issued on Wednesday, MarketBeat reports. They currently have a $1.00 price objective on the stock, down from their prior price objective of $5.00. Wells Fargo & Company‘s target price would suggest a potential downside of 14.53% from the company’s current price.

Several other equities research analysts have also commented on the stock. Raymond James Financial set a $3.00 target price on shares of Health Catalyst in a research report on Friday. Stephens reduced their price objective on shares of Health Catalyst from $3.50 to $2.00 and set an “equal weight” rating for the company in a research note on Friday, March 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Health Catalyst in a report on Monday, December 29th. Canaccord Genuity Group lowered their target price on shares of Health Catalyst from $5.00 to $2.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Cantor Fitzgerald lowered their target price on shares of Health Catalyst from $4.00 to $3.00 and set a “neutral” rating on the stock in a research report on Friday. Four analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Health Catalyst presently has an average rating of “Hold” and an average target price of $2.80.

Health Catalyst Stock Down 3.7%

HCAT opened at $1.17 on Wednesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.89 and a quick ratio of 1.89. Health Catalyst has a 12 month low of $1.16 and a 12 month high of $5.06. The stock has a market capitalization of $86.10 million, a P/E ratio of -0.46 and a beta of 1.77. The business has a 50 day simple moving average of $2.01 and a 200-day simple moving average of $2.52.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Thursday, March 12th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.02). The business had revenue of $74.68 million for the quarter, compared to analyst estimates of $73.99 million. Health Catalyst had a negative return on equity of 4.30% and a negative net margin of 57.20%. On average, equities analysts anticipate that Health Catalyst will post -0.33 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in HCAT. nVerses Capital LLC purchased a new stake in shares of Health Catalyst in the 4th quarter worth about $25,000. Pilgrim Partners Asia Pte Ltd purchased a new position in Health Catalyst during the 3rd quarter valued at about $39,000. Cresset Asset Management LLC acquired a new position in Health Catalyst during the second quarter worth about $39,000. FNY Investment Advisers LLC acquired a new position in Health Catalyst during the third quarter worth about $45,000. Finally, Focus Partners Wealth purchased a new stake in shares of Health Catalyst in the first quarter valued at about $46,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.